Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Eli Lilly stock was falling early Thursday even as the drugmaker posted first-quarter earnings that beat analysts’ expectations. This is breaking news. Read a preview of Eli Lilly below and check back ...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 11% in the afternoon session after the company reported weak first quarter 2025 results which included an EPS miss due ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Shares of Eli Lilly & Co. LLY advanced 2.48% to $733.29 Thursday, on what proved to be an all-around great trading session ...

Eli Lilly stock (NYSE: LLY) is gaining momentum on Thursday, April 17th, following the company’s announcement of successful results from the first of its late-stage trials for a daily obesity pill.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Eli Lilly stock (NYSE: LLY) stock is showing positive momentum on Thursday, April 17th, following the company’s announcement of successful results from the first of its late-stage trials for a ...

To watch more expert insights and analysis on the latest market action ... Despite these headline-grabbing results, Eli Lilly's stock movement remained flat over the last month, aligning with ...

Eli Lilly (NYSE:LLY) shares climbed ~14% in the ... weight as they hadn’t reached a weight plateau at the time of the analysis. However, for the treatment regimen estimand, which considers ...

Eli Lilly (LLY) stock surges after releasing promising test ... To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. Eli Lilly shares surging ...

INDIANAPOLIS, Nov. 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: NYSE:LLY) today announced that data from the Phase 3 ...